Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis

[1]  A. Tefferi,et al.  Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents , 2022, Blood advances.

[2]  H. Döhner,et al.  Towards precision medicine for AML , 2021, Nature Reviews Clinical Oncology.

[3]  B. Leber,et al.  Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial , 2019, Annals of Hematology.

[4]  A. Logan,et al.  Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia , 2020, Transplantation and Cellular Therapy.

[5]  G. Marcucci,et al.  Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML) , 2020 .

[6]  H. Döhner,et al.  Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Letai,et al.  Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study , 2020, American journal of hematology.

[8]  H. Döhner,et al.  Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. , 2020, Blood.

[9]  G. Marcucci,et al.  Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[11]  B. Leber,et al.  Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy , 2020, Journal of Hematology & Oncology.

[12]  High Risk Myelodysplastic Syndrome , 2020, Definitions.

[13]  D. Oxborough,et al.  Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: a guideline from the British Society of Echocardiography , 2020, Echo research and practice.

[14]  A. Kuan,et al.  The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia , 2020, Cancer medicine.

[15]  C. Dinardo,et al.  How I treat acute myeloid leukemia in the era of new drugs. , 2019, Blood.

[16]  H. Döhner,et al.  Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study , 2019, Blood.

[17]  P. Vyas,et al.  Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia , 2019, Blood.

[18]  R. Larson,et al.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.

[19]  H. Kent Holland,et al.  Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program , 2019, Bone Marrow Transplantation.

[20]  M. Salas,et al.  A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States. , 2019, Clinical lymphoma, myeloma & leukemia.

[21]  Xiaomei Ma,et al.  Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.

[22]  R. Larson,et al.  Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). , 2019, Blood advances.

[23]  A. Wei,et al.  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[25]  M. Heuser,et al.  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome , 2018, Leukemia.

[26]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[27]  M. Tallman,et al.  How I Treat How I treat acute myeloid leukemia presenting with preexisting comorbidities , 2016 .

[28]  L. Kremer,et al.  Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. , 2016, The Cochrane database of systematic reviews.

[29]  Smith Giri,et al.  Early mortality in acute myeloid leukemia. , 2015, Leukemia research.

[30]  R. Hills,et al.  A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. , 2014, Blood.

[31]  G. Behre,et al.  Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation , 2015, Journal of Cancer Research and Clinical Oncology.

[32]  M. Nørgaard,et al.  Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study , 2014, Leukemia.

[33]  M. Bansal.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013 .

[34]  J. Esteve,et al.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of , 2013, Journal of the American College of Cardiology.

[35]  B. Leber,et al.  Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus. , 2013, American journal of blood research.

[36]  A. Wei,et al.  Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse , 2013, Leukemia & lymphoma.

[37]  S. Zimeras,et al.  Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up , 2010, American journal of hematology.

[38]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[39]  W. Berdel,et al.  Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis. , 2008, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[40]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[41]  J. Castro,et al.  Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. , 2006, Leukemia research.

[42]  T. Ahmed,et al.  Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia , 1991, Cancer.

[43]  H. König,et al.  Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results. , 1989, Onkologie.

[44]  M. Andreeff,et al.  Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. , 1989, Leukemia.